Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation and aggregation into neurofibrillary tangles (right). [Courtesy of Eli ...

In Japan, clinical use is climbing faster, with about 4,500 people now on the drug. ARIA rates in Japan are half those in the U.S., which was also the case in the Phase 3 Clarity trial. Meanwhile, use ...

Do you know a conference you think we should list? Let us know by sending us an email with the details to [email protected].

In recent years, CryoEM has enabled scientists to decipher the structures of the fibrils that form various deposits in neurodegenerative disease. They have not only solved disease-specific folding ...

“Bruce had a brilliant career in both academia and industry and left an indelible mark on the Alzheimer’s disease drug development landscape,” noted Robert Vassar, Northwestern University, Chicago ...

Seeking ways to improve the safety of anti-amyloid antibodies, John Sims of Eli Lilly & Company presented a simple option to do so for donanemab at this year’s Clinical Trials on Alzheimer’s Disease ...

B.A. in Psychology from Duquesne U 1971 M.A. in Psychology coursework completed all but Thesis U of Dallas 1973-75 M.A. coursework in Infomation Science at U of Pittsburgh 1995-1997 ...

Wayne Shotts, Physics Ph.D., B.A.

SORL1 knockout, knockin, and transgenic mice are now in the Research Models database. The database will be updated as more models become available.

Already have an account? Log in.

You are not authorized to access this site.

These tau knockout rats were created through transcription activator-like effector nuclease (TALEN)-mediated targeting of exon 2 of the rat Mapt gene (Ayers, Lopez et al., 2024). Tau protein was ...